Aptose Biosciences initiated with an Outperform at Oppenheimer. As previously reported, Oppenheimer analyst Matthew Biegler initiated Aptose Biosciences with an Outperform rating and $6 price target, citing the commercial potential of CG-806 in two major hematology/oncology indications. In a research note to investors, Biegler says he believes CG-806 can selectively disable key signaling pathways that cancer cells need without the “safety baggage” usually associated with multi-kinase inhibitors. Biegler says he would be a buyer of Aptose ahead of CG-806’s expected 1H19 entry into the clinic.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.